Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab-Reference-Cited by-同舟云学术

Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab

Published:2021-09 Issue:9 Volume:32 Page:1193-1194
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Fabrizio D.,Cristescu R.,Albacker L.,Snyder A.,Ward A.,Lunceford J.,Aurora-Garg D.,Jin F.,Hopkins J.,Rubin E.,Hegde P.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference4 articles.

1. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types;McGrail;Ann Oncol,2021

2. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study;Marabelle;Lancet Oncol,2020

3. Analysis of 100,000 cancer genomes reveals the landscape of tumor mutational burden;Chalmers;Genome Med,2017

4. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers;Goodman;Mol Cancer Ther,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of Genomic Landscape on Cancer Immunotherapy for Newly Diagnosed Ovarian Cancer: Biomarker Analyses from the IMagyn050 Randomized Clinical Trial;Clinical Cancer Research;2023-01-03

2. Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay;Annals of Oncology;2022-11

3. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies;Journal for ImmunoTherapy of Cancer;2022-06

4. ctDNA-Profiling-Based UBL Biological Process Mutation Status as a Predictor of Atezolizumab Response Among TP53-Negative NSCLC Patients;Frontiers in Genetics;2021-09-07

5. Reply to: ‘Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.’ by D. Fabrizio et al.;Annals of Oncology;2021-09